Evaluating the efficacy of transrectal povidone-iodine application for infection prevention in transrectal ultrasound-guided prostate biopsy: A single-center retrospective study.

Q3 Medicine

Medical Journal of Malaysia Pub Date : 2025-09-01

M H Azizi, M H Mohd Hashim, L Y Lim, H C Khoo, Z Md Zainuddin, N S Che Razali

{"title":"Evaluating the efficacy of transrectal povidone-iodine application for infection prevention in transrectal ultrasound-guided prostate biopsy: A single-center retrospective study.","authors":"M H Azizi, M H Mohd Hashim, L Y Lim, H C Khoo, Z Md Zainuddin, N S Che Razali","doi":"","DOIUrl":null,"url":null,"abstract":"Introduction: Prostate cancer diagnosis via transrectal ultrasound-guided (TRUS) biopsy carries a significant risk of infectious complications due to potential contamination from the rectal microbiome. This study aimed to evaluate the efficacy of transrectal 10% povidone-iodine application, in combination with antibiotic prophylaxis, in reducing infectious complications following TRUS biopsy.Materials and methods: A retrospective analysis was conducted on 643 patients who underwent TRUS biopsy at a single center in a tertiary hospital in Kuala Lumpur between January 2017 and December 2023. Patient records were reviewed for demographic data, biopsy indications, type of antibiotic prophylaxis, and post-biopsy complications. Patients were categorized into two groups: those who received antibiotic prophylaxis alone and those who received both antibiotic prophylaxis and transrectal povidone-iodine. Statistical analyses, including chi-square tests and logistic regression, were performed to compare outcomes and assess the impact of povidone-iodine on infection rates.Results: Of the 643 patients, 285 received antibiotic prophylaxis combined with transrectal povidone-iodine, was associated with a significantly lower infection rate from 2.23% to 0.7% (P < 0.05). There were no significant differences between the povidone-iodine and non- povidone-iodine groups in terms of patient demographics, including age, prostate volume, Prostate Specific Antigen (PSA) levels, and histopathological findings. Logistic regression analysis further confirmed the significant effect of povidone-iodine in reducing post-biopsy infections presenting as fever >37.5 within 30 days after TRUS biopsy.Conclusion: The results indicate that the use of transrectal 10% povidone-iodine alongside antibiotic prophylaxis is an effective approach for reducing infectious complications following TRUS biopsy.","PeriodicalId":39388,"journal":{"name":"Medical Journal of Malaysia","volume":"80 5","pages":"589-593"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Journal of Malaysia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Prostate cancer diagnosis via transrectal ultrasound-guided (TRUS) biopsy carries a significant risk of infectious complications due to potential contamination from the rectal microbiome. This study aimed to evaluate the efficacy of transrectal 10% povidone-iodine application, in combination with antibiotic prophylaxis, in reducing infectious complications following TRUS biopsy.

Materials and methods: A retrospective analysis was conducted on 643 patients who underwent TRUS biopsy at a single center in a tertiary hospital in Kuala Lumpur between January 2017 and December 2023. Patient records were reviewed for demographic data, biopsy indications, type of antibiotic prophylaxis, and post-biopsy complications. Patients were categorized into two groups: those who received antibiotic prophylaxis alone and those who received both antibiotic prophylaxis and transrectal povidone-iodine. Statistical analyses, including chi-square tests and logistic regression, were performed to compare outcomes and assess the impact of povidone-iodine on infection rates.

Results: Of the 643 patients, 285 received antibiotic prophylaxis combined with transrectal povidone-iodine, was associated with a significantly lower infection rate from 2.23% to 0.7% (P < 0.05). There were no significant differences between the povidone-iodine and non- povidone-iodine groups in terms of patient demographics, including age, prostate volume, Prostate Specific Antigen (PSA) levels, and histopathological findings. Logistic regression analysis further confirmed the significant effect of povidone-iodine in reducing post-biopsy infections presenting as fever >37.5 within 30 days after TRUS biopsy.

Conclusion: The results indicate that the use of transrectal 10% povidone-iodine alongside antibiotic prophylaxis is an effective approach for reducing infectious complications following TRUS biopsy.

本刊更多论文

评估经直肠超声引导前列腺活检中应用聚维酮碘预防感染的效果：一项单中心回顾性研究。

导读：由于直肠微生物群的潜在污染，经直肠超声引导（TRUS）活检诊断前列腺癌具有显著的感染并发症风险。本研究旨在评估经直肠应用10%聚维酮碘，联合抗生素预防，减少TRUS活检后感染并发症的疗效。材料和方法：对2017年1月至2023年12月期间在吉隆坡一家三级医院的单一中心接受TRUS活检的643例患者进行回顾性分析。回顾患者记录的人口统计数据、活检指征、抗生素预防类型和活检后并发症。患者分为两组：单独接受抗生素预防治疗的患者和同时接受抗生素预防治疗和经直肠聚维酮碘治疗的患者。统计分析包括卡方检验和逻辑回归，以比较结果并评估聚维酮碘对感染率的影响。结果：643例患者中抗生素预防联合经直肠聚维酮碘治疗285例，感染率由2.23%降至0.7% （P < 0.05）。聚维酮碘组和非聚维酮碘组在患者人口统计学方面无显著差异，包括年龄、前列腺体积、前列腺特异性抗原（PSA）水平和组织病理学结果。Logistic回归分析进一步证实聚维酮碘对减少TRUS活检后30天内出现发热bbb37.5的活检后感染有显著作用。结论：经直肠10%聚维酮碘联合抗生素预防是减少TRUS活检后感染并发症的有效方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical Journal of Malaysia Medicine-Medicine (all)

CiteScore

1.20

自引率

0.00%

发文量

165

期刊介绍： Published since 1890 this journal originated as the Journal of the Straits Medical Association. With the formation of the Malaysian Medical Association (MMA), the Journal became the official organ, supervised by an editorial board. Some of the early Hon. Editors were Mr. H.M. McGladdery (1960 - 1964), Dr. A.A. Sandosham (1965 - 1977), Prof. Paul C.Y. Chen (1977 - 1987). It is a scientific journal, published quarterly and can be found in medical libraries in many parts of the world. The Journal also enjoys the status of being listed in the Index Medicus, the internationally accepted reference index of medical journals. The editorial columns often reflect the Association''s views and attitudes towards medical problems in the country. The MJM aims to be a peer reviewed scientific journal of the highest quality. We want to ensure that whatever data is published is true and any opinion expressed important to medical science. We believe being Malaysian is our unique niche; our priority will be for scientific knowledge about diseases found in Malaysia and for the practice of medicine in Malaysia. The MJM will archive knowledge about the changing pattern of human diseases and our endeavours to overcome them. It will also document how medicine develops as a profession in the nation. We will communicate and co-operate with other scientific journals in Malaysia. We seek articles that are of educational value to doctors. We will consider all unsolicited articles submitted to the journal and will commission distinguished Malaysians to write relevant review articles. We want to help doctors make better decisions and be good at judging the value of scientific data. We want to help doctors write better, to be articulate and precise.